Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization
Corresponding Author
Esozia Arroabarren
Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorElena Aznal
Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorMarta Anda
Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorFelix Sanchez-Valverde
Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorCorresponding Author
Esozia Arroabarren
Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorElena Aznal
Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorMarta Anda
Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this authorFelix Sanchez-Valverde
Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
Search for more papers by this author
REFERENCES
- 1Hendriksz C, Santra S, Jones SA, et al. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment. Mol Genet Metab. 2018; 123(4): 479-487.
- 2Hendriksz CJ, Parini R, AlSayed MD, et al. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Mol Genet Metab. 2018; 123(2): 127-134.
- 3Aranda CS, Ensina LF, Nunes IC, et al. Diagnosis and management of infusion-related hypersensitivity reactions to enzyme replacement therapy for lysosomal diseases: The role of desensitization. J Allergy Clin Immunol Pract. 2016; 4(2): 354-356.
- 4Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002; 57(1): 45-51.
- 5Steiner M, Harrer A, Himly M. Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations. Front Pharmacol. 2016; 7: 171.
- 6Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab. 2009; 98(3): 319-321.
- 7Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy. 2010; 65(11): 1357-1366.
- 8Rohrbach M, Klein A, Kohli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis. 2010; 33(6): 751-757.
- 9Ensina LF, Aranda C, Carmelo I, Martins AM, Dirceu S. Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis patient. Paper presented at: 7th Drug Hypersensitivity Meeting. April 21-23, 2016; Malaga, Spain.
- 10van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10): 777-787.
- 11Guvenir H, Dibek Misirlioglu E, Capanoglu M, et al. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome. J Allergy Clin Immunol Pract. 2017; 5(4): 1156-1157.
Citing Literature
